Genfit Hopes To Make Case For First-Line Treatment In NASH

French company expects Phase III data later in 2019 that will demonstrate elafibranor’s ability to resolve NASH without worsening of fibrosis. Genfit also is partnered with Covance on a potential diagnostic test for NASH.

Healthy Liver

Heading into the European Association for the Study of the Liver meeting April 10-14, Genfit SA is anticipating the release of Phase III data toward year’s end that it thinks may position elafibranor as the first-line drug therapy in non-alcoholic steatohepatitis (NASH) as well as a potential backbone of combination therapy in the disease.

Genfit R&D Director Dean Hum told Scrip that his company believes elafibranor – a peroxisome proliferator accelerator receptor (PPAR) alpha/delta...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Alimentary/Metabolic

More from Therapy Areas

Will AstraZeneca Reach Summit And Be A PD-1xVEGF Player?

 
• By 

Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.

Compass Pathways’ Antidepressant Advances In An Increasingly Tough Psychedelic Market

 
• By 

Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.

Eolo Pharma Advances In Obesity With Thermogenesis Approach

 
• By 

Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.